BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,920 | -99.8% | 24,600 | -97.5% | 0.00% | – |
| Q2 2023 | $2,011,382 | -18.7% | 976,399 | +30.2% | 0.00% | – |
| Q1 2023 | $2,474,845 | +577.7% | 749,953 | +236.8% | 0.00% | – |
| Q4 2022 | $365,180 | -80.8% | 222,671 | -48.2% | 0.00% | – |
| Q3 2022 | $1,899,000 | +16.6% | 429,700 | -27.1% | 0.00% | – |
| Q2 2022 | $1,628,000 | -4.5% | 589,623 | +16.3% | 0.00% | – |
| Q1 2022 | $1,705,000 | -60.6% | 507,200 | -53.1% | 0.00% | – |
| Q4 2021 | $4,326,000 | +68.0% | 1,081,400 | +38.6% | 0.00% | – |
| Q3 2021 | $2,575,000 | -28.6% | 780,231 | -17.7% | 0.00% | – |
| Q2 2021 | $3,605,000 | +16.5% | 948,600 | +17.4% | 0.00% | – |
| Q1 2021 | $3,095,000 | -65.2% | 808,019 | -58.9% | 0.00% | – |
| Q4 2020 | $8,894,000 | +3.5% | 1,965,498 | +286.9% | 0.00% | -100.0% |
| Q3 2020 | $8,596,000 | +70.8% | 508,000 | +13.1% | 0.00% | +100.0% |
| Q2 2020 | $5,034,000 | +162.6% | 449,000 | +8.7% | 0.00% | – |
| Q1 2020 | $1,917,000 | +391.5% | 413,200 | +354.5% | 0.00% | – |
| Q4 2019 | $390,000 | -36.5% | 90,906 | -42.3% | 0.00% | – |
| Q3 2019 | $614,000 | -71.7% | 157,516 | -71.3% | 0.00% | – |
| Q2 2019 | $2,169,000 | +285.3% | 549,101 | +324.0% | 0.00% | – |
| Q1 2019 | $563,000 | +463.0% | 129,513 | +361.9% | 0.00% | – |
| Q4 2018 | $100,000 | +35.1% | 28,039 | +45.4% | 0.00% | – |
| Q3 2018 | $74,000 | -15.9% | 19,281 | -14.5% | 0.00% | – |
| Q2 2018 | $88,000 | -74.3% | 22,551 | -74.2% | 0.00% | – |
| Q4 2017 | $342,000 | -20.1% | 87,323 | -15.9% | 0.00% | – |
| Q3 2017 | $428,000 | +275.4% | 103,792 | +280.2% | 0.00% | – |
| Q2 2017 | $114,000 | -55.8% | 27,300 | -55.1% | 0.00% | – |
| Q1 2017 | $258,000 | +73.2% | 60,800 | -2.6% | 0.00% | – |
| Q3 2016 | $149,000 | +198.0% | 62,400 | +233.1% | 0.00% | – |
| Q1 2016 | $50,000 | -31.5% | 18,733 | -41.5% | 0.00% | – |
| Q3 2015 | $73,000 | – | 32,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |